A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05130424

Enrollment

498

Registered

2021-11-23

Start date

2021-09-29

Completion date

2023-09-30

Last updated

2021-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma;Blood

Brief summary

To observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in Henan Province

Detailed description

This study is designed as a real-world study on the treatment of thrombocytopenia-related diseases with Herombopag, to observe and analyze the safety and efficacy of Herombopag for thrombocytopenia-related diseases in the real world.

Interventions

DRUGHerombopag

Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Thrombocytopenia related diseases; 2. Volunteer to join this study and sign an informed consent form; 3. Clinical evaluation can benefit from Herombopag.

Exclusion criteria

1. Those who have been confirmed to be allergic to Herombopag and/or its excipients; 2. Pregnant or breastfeeding women; 3. Except for patients with contraindications to Herombopag; 4. Doctors evaluate patients who are not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of adverse events after the treatment of Herombopag	From the treatment of Herombopag to 28 days after the end of the medication	The investigator will observe incidence of adverse events after the treatment of Herombopag, including thrombosis, diarrhea, abnormal liver function and so on.

Secondary

Measure	Time frame	Description
Changes of the platelet counts after the treatment of Herombopag	From the treatment of Herombopag to 28 days after the end of the medication	The investigator will assess the changes of the platelet counts after the treatment of Herombopag。
Proportion of patients with platelet transfusion	From the treatment of Herombopag to 28 days after the end of the medication	The investigator will assess the proportion of patients with platelet transfusion after the treatment of Herombopag。

Countries

China

Contacts

Primary Contactsuxia luo

luosxrm@163.com18638553211

Backup Contactwenying deng

psc1969@sohu.com15837168169

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026